Pinnbrook Capital Management LP Invests $5.78 Million in Natera, Inc. $NTRA

Pinnbrook Capital Management LP purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the third quarter, HoldingsChannel reports. The fund purchased 35,914 shares of the medical research company’s stock, valued at approximately $5,781,000.

Several other institutional investors have also recently added to or reduced their stakes in NTRA. JPMorgan Chase & Co. boosted its stake in Natera by 44.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Norges Bank bought a new stake in shares of Natera in the 2nd quarter worth about $277,749,000. Franklin Resources Inc. increased its position in shares of Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Natera by 44.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock valued at $291,717,000 after purchasing an additional 532,769 shares in the last quarter. Finally, Holocene Advisors LP lifted its position in shares of Natera by 118.3% during the second quarter. Holocene Advisors LP now owns 572,832 shares of the medical research company’s stock worth $96,774,000 after purchasing an additional 310,452 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on NTRA shares. Guggenheim lifted their price target on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Morgan Stanley cut their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Wells Fargo & Company increased their target price on Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Robert W. Baird boosted their price target on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $253.47.

Natera Stock Performance

NASDAQ NTRA opened at $187.85 on Friday. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The company has a 50-day simple moving average of $219.73 and a 200-day simple moving average of $206.14. The firm has a market capitalization of $26.62 billion, a PE ratio of -122.78 and a beta of 1.65.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the prior year, the business earned ($0.41) earnings per share. Equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In related news, insider John Fesko sold 17,806 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $4,179,780.44. Following the sale, the insider owned 177,591 shares of the company’s stock, valued at approximately $41,687,711.34. This trade represents a 9.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 23,205 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider directly owned 144,992 shares in the company, valued at approximately $34,035,422.08. This trade represents a 13.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 318,222 shares of company stock valued at $74,068,068 over the last three months. 5.63% of the stock is owned by company insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.